Selected research
Market Outlook & Growth Opportunities
Global Antithrombin Market Outlook and Growth Opportunities 2026
Market perspective
The global Antithrombin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Antithrombin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Antithrombin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Antithrombin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Antithrombin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Antithrombin market include Takeda, Scripps Laboratories Inc., Grifols, rEVO Biologics Inc., Lee Biosolutions, Kedrion S.p.A. and CSL Limited, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Antithrombin market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Antithrombin and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Antithrombin revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Antithrombin market.
Antithrombin Segment by Company
Takeda
Scripps Laboratories Inc.
Grifols
rEVO Biologics Inc.
Lee Biosolutions
Kedrion S.p.A.
CSL Limited
Antithrombin Segment by Type
Liquid
Lyophilized
Antithrombin Segment by Application
Diagnostics
Research
Therapeutics
Antithrombin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Antithrombin status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Antithrombin key companies, revenue, market share, and recent developments.
3. To split the Antithrombin breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Antithrombin market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Antithrombin significant trends, drivers, influence factors in global and regions.
6. To analyze Antithrombin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antithrombin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antithrombin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antithrombin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antithrombin industry.
Chapter 3: Detailed analysis of Antithrombin company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Antithrombin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Antithrombin in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Liquid
- Lyophilized
Applications
- Diagnostics
- Research
- Therapeutics
Companies covered
- Takeda
- Scripps Laboratories Inc.
- Grifols
- rEVO Biologics Inc.
- Lee Biosolutions
- Kedrion S.p.A.
- CSL Limited
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Antithrombin Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Antithrombin Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Antithrombin Market Dynamics
- 2.1 Antithrombin Industry Trends
- 2.2 Antithrombin Industry Drivers
- 2.3 Antithrombin Industry Opportunities and Challenges
- 2.4 Antithrombin Industry Restraints
3 Antithrombin Market by Company
- 3.1 Global Antithrombin Company Revenue Ranking in 2025
- 3.2 Global Antithrombin Revenue by Company (2021-2026)
- 3.3 Global Antithrombin Company Ranking (2024-2026)
- 3.4 Global Antithrombin Company Manufacturing Base and Headquarters
- 3.5 Global Antithrombin Company Product Type and Application
- 3.6 Global Antithrombin Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Antithrombin Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Antithrombin Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Antithrombin Market by Type
- 4.1 Antithrombin Type Introduction
- 4.1.1 Liquid
- 4.1.2 Lyophilized
- 4.2 Global Antithrombin Sales Value by Type
- 4.2.1 Global Antithrombin Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Antithrombin Sales Value by Type (2021-2032)
- 4.2.3 Global Antithrombin Sales Value Share by Type (2021-2032)
5 Antithrombin Market by Application
- 5.1 Antithrombin Application Introduction
- 5.1.1 Diagnostics
- 5.1.2 Research
- 5.1.3 Therapeutics
- 5.2 Global Antithrombin Sales Value by Application
- 5.2.1 Global Antithrombin Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Antithrombin Sales Value by Application (2021-2032)
- 5.2.3 Global Antithrombin Sales Value Share by Application (2021-2032)
6 Antithrombin Regional Value Analysis
- 6.1 Global Antithrombin Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Antithrombin Sales Value by Region (2021-2032)
- 6.2.1 Global Antithrombin Sales Value by Region: 2021-2026
- 6.2.2 Global Antithrombin Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Antithrombin Sales Value (2021-2032)
- 6.3.2 North America Antithrombin Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Antithrombin Sales Value (2021-2032)
- 6.4.2 Europe Antithrombin Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Antithrombin Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Antithrombin Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Antithrombin Sales Value (2021-2032)
- 6.6.2 South America Antithrombin Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Antithrombin Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Antithrombin Sales Value Share by Country, 2025 VS 2032
7 Antithrombin Country-level Value Analysis
- 7.1 Global Antithrombin Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Antithrombin Sales Value by Country (2021-2032)
- 7.2.1 Global Antithrombin Sales Value by Country (2021-2026)
- 7.2.2 Global Antithrombin Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Antithrombin Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Antithrombin Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Antithrombin Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Antithrombin Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Antithrombin Sales Value Growth Rate (2021-2032)
- 7.7.2 France Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Antithrombin Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Antithrombin Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Antithrombin Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Antithrombin Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Antithrombin Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Antithrombin Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Antithrombin Sales Value Growth Rate (2021-2032)
- 7.14.2 China Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Antithrombin Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Antithrombin Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Antithrombin Sales Value Growth Rate (2021-2032)
- 7.17.2 India Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Antithrombin Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Antithrombin Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Antithrombin Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Antithrombin Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Antithrombin Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Antithrombin Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Antithrombin Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Antithrombin Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Antithrombin Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Antithrombin Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Antithrombin Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Antithrombin Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Antithrombin Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Antithrombin Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Antithrombin Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Antithrombin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Takeda
- 8.1.1 Takeda Company Information
- 8.1.2 Takeda Business Overview
- 8.1.3 Takeda Antithrombin Revenue and Gross Margin (2021-2026)
- 8.1.4 Takeda Antithrombin Product Portfolio
- 8.1.5 Takeda Recent Developments
- 8.2 Scripps Laboratories Inc.
- 8.2.1 Scripps Laboratories Inc. Company Information
- 8.2.2 Scripps Laboratories Inc. Business Overview
- 8.2.3 Scripps Laboratories Inc. Antithrombin Revenue and Gross Margin (2021-2026)
- 8.2.4 Scripps Laboratories Inc. Antithrombin Product Portfolio
- 8.2.5 Scripps Laboratories Inc. Recent Developments
- 8.3 Grifols
- 8.3.1 Grifols Company Information
- 8.3.2 Grifols Business Overview
- 8.3.3 Grifols Antithrombin Revenue and Gross Margin (2021-2026)
- 8.3.4 Grifols Antithrombin Product Portfolio
- 8.3.5 Grifols Recent Developments
- 8.4 rEVO Biologics Inc.
- 8.4.1 rEVO Biologics Inc. Company Information
- 8.4.2 rEVO Biologics Inc. Business Overview
- 8.4.3 rEVO Biologics Inc. Antithrombin Revenue and Gross Margin (2021-2026)
- 8.4.4 rEVO Biologics Inc. Antithrombin Product Portfolio
- 8.4.5 rEVO Biologics Inc. Recent Developments
- 8.5 Lee Biosolutions
- 8.5.1 Lee Biosolutions Company Information
- 8.5.2 Lee Biosolutions Business Overview
- 8.5.3 Lee Biosolutions Antithrombin Revenue and Gross Margin (2021-2026)
- 8.5.4 Lee Biosolutions Antithrombin Product Portfolio
- 8.5.5 Lee Biosolutions Recent Developments
- 8.6 Kedrion S.p.A.
- 8.6.1 Kedrion S.p.A. Company Information
- 8.6.2 Kedrion S.p.A. Business Overview
- 8.6.3 Kedrion S.p.A. Antithrombin Revenue and Gross Margin (2021-2026)
- 8.6.4 Kedrion S.p.A. Antithrombin Product Portfolio
- 8.6.5 Kedrion S.p.A. Recent Developments
- 8.7 CSL Limited
- 8.7.1 CSL Limited Company Information
- 8.7.2 CSL Limited Business Overview
- 8.7.3 CSL Limited Antithrombin Revenue and Gross Margin (2021-2026)
- 8.7.4 CSL Limited Antithrombin Product Portfolio
- 8.7.5 CSL Limited Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst